Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 373.4 g/mol |
|---|---|
| Molecular Formula | C21H15N3O4 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 373.10625597 g/mol |
| Monoisotopic Mass | 373.10625597 g/mol |
| Topological Polar Surface Area | 98.7 A^2 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 912 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Exjade |
| PubMed Health | Deferasirox (By mouth) |
| Drug Classes | Heavy Metal Chelator |
| Drug Label | Exjade(deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125mg, 250mg, or 500mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its st... |
| Active Ingredient | Deferasirox |
| Dosage Form | Tablet, for suspension |
| Route | Oral |
| Strength | 250mg; 125mg; 500mg |
| Market Status | Prescription |
| Company | Novartis |
| 2 of 2 | |
|---|---|
| Drug Name | Exjade |
| PubMed Health | Deferasirox (By mouth) |
| Drug Classes | Heavy Metal Chelator |
| Drug Label | Exjade(deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125mg, 250mg, or 500mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its st... |
| Active Ingredient | Deferasirox |
| Dosage Form | Tablet, for suspension |
| Route | Oral |
| Strength | 250mg; 125mg; 500mg |
| Market Status | Prescription |
| Company | Novartis |
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
Registrant Name : Gunil Pharmaceutical Co., Ltd.
Registration Date : 2017-07-27
Registration Number : Number 2816-7-ND(1)
Manufacturer Name : Farmak, as
Manufacturer Address : Na vlcinci 16/3, Klasterni Hradisko, 779 00 Olomouc, Czech Republic
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2020-06-30
Registration Number : Su434-12-ND
Manufacturer Name : Neuland Laboratories Limited...
Manufacturer Address : Plot No. 92-94, 257-259 IDA, Pashamylaram, Isnapur Village, Patancheru Mandal, Sangar...
Registrant Name : Seongwoo Chemical Co., Ltd.
Registration Date : 2016-07-26
Registration Number : Su4579-13-ND
Manufacturer Name : Alembic Pharmaceuticals Limi...
Manufacturer Address : Panelav, POTajpura, Taluka-Halol, District- Panchmahal-389 350, Gujarat State, India

Registrant Name : MPK Korea Co., Ltd.
Registration Date : 2017-04-28
Registration Number : Su55-3-ND
Manufacturer Name : Alivus Life Sciences Limited
Manufacturer Address : Plot No. Z-103/Ⅰ, DAHEJ SEZ., Phase Ⅱ, City : Dahej, District : Bharuch, Gujara...

Registrant Name : Daewon Pharmaceutical Co., Ltd.
Registration Date : 2017-01-17
Registration Number : Number 4838-18-ND(1)
Manufacturer Name : Cipla Limited
Manufacturer Address : D-22, MIDC Industrial Area, Kurkumbh, Taluka Daund, District : Pune, Maharashtra Stat...

Registrant Name : Korea Pharmbio Co., Ltd.
Registration Date : 2017-05-04
Registration Number : Number 4838-18-ND(2)
Manufacturer Name : Cipla Limited
Manufacturer Address : D-22, MIDC Industrial Area, Kurkumbh, Taluka Daund, District: Pune, Maharashtra State

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2017-08-08
Registration Number : Su258-3-ND
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...

Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2018-02-21
Registration Number : Number 258-3-ND(1)
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...

Registrant Name : SK Biotech Co., Ltd.
Registration Date : 2022-08-29
Registration Number : 940-1-ND
Manufacturer Name : SK Biotech Co., Ltd.
Manufacturer Address : 80 Myeonghaksandan-ro, Yeondong-myeon, Sejong Special Self-Governing City

Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2018-03-22
Registration Number : Number 2816-1-ND(2)
Manufacturer Name : Mylan Laboratories Limited
Manufacturer Address : Unit-8, G.Chodavaram, Pusapatirega Mandal, Vizianagaram District-535204, Andhra Prade...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Defloxol
Dosage Form : Film Coated Tablet
Dosage Strength : 180mg
Packaging :
Approval Date : 20-12-2021
Application Number : 28106311119
Regulatory Info : Prescription
Registration Country : Denmark
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Defloxol
Dosage Form : Film Coated Tablet
Dosage Strength : 360mg
Packaging :
Approval Date : 20-12-2021
Application Number : 28106311219
Regulatory Info : Prescription
Registration Country : Denmark
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Defloxol
Dosage Form : Film Coated Tablet
Dosage Strength : 90mg
Packaging :
Approval Date : 20-12-2021
Application Number : 28106311019
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info : RX
Registration Country : USA
Brand Name : DEFERASIROX
Dosage Form : GRANULE;ORAL
Dosage Strength : 90MG
Packaging :
Approval Date : 2021-03-09
Application Number : 214559
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : DEFERASIROX
Dosage Form : GRANULE;ORAL
Dosage Strength : 180MG
Packaging :
Approval Date : 2021-03-09
Application Number : 214559
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : DEFERASIROX
Dosage Form : GRANULE;ORAL
Dosage Strength : 360MG
Packaging :
Approval Date : 2021-03-09
Application Number : 214559
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : U.S.A
Brand Name :
Dosage Form : Oral Granule
Dosage Strength : 360MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : U.S.A
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Tablet
Dosage Strength : 90MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Tablet
Dosage Strength : 180MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Tablet
Dosage Strength : 360MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
10
PharmaCompass offers a list of Deferasirox API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Deferasirox manufacturer or Deferasirox supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deferasirox manufacturer or Deferasirox supplier.
A Deferasirox manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deferasirox, including repackagers and relabelers. The FDA regulates Deferasirox manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deferasirox API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deferasirox manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Deferasirox supplier is an individual or a company that provides Deferasirox active pharmaceutical ingredient (API) or Deferasirox finished formulations upon request. The Deferasirox suppliers may include Deferasirox API manufacturers, exporters, distributors and traders.
click here to find a list of Deferasirox suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Deferasirox DMF (Drug Master File) is a document detailing the whole manufacturing process of Deferasirox active pharmaceutical ingredient (API) in detail. Different forms of Deferasirox DMFs exist exist since differing nations have different regulations, such as Deferasirox USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deferasirox DMF submitted to regulatory agencies in the US is known as a USDMF. Deferasirox USDMF includes data on Deferasirox's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deferasirox USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deferasirox suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Deferasirox Drug Master File in Japan (Deferasirox JDMF) empowers Deferasirox API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Deferasirox JDMF during the approval evaluation for pharmaceutical products. At the time of Deferasirox JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Deferasirox suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Deferasirox Drug Master File in Korea (Deferasirox KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Deferasirox. The MFDS reviews the Deferasirox KDMF as part of the drug registration process and uses the information provided in the Deferasirox KDMF to evaluate the safety and efficacy of the drug.
After submitting a Deferasirox KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Deferasirox API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Deferasirox suppliers with KDMF on PharmaCompass.
A Deferasirox CEP of the European Pharmacopoeia monograph is often referred to as a Deferasirox Certificate of Suitability (COS). The purpose of a Deferasirox CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Deferasirox EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Deferasirox to their clients by showing that a Deferasirox CEP has been issued for it. The manufacturer submits a Deferasirox CEP (COS) as part of the market authorization procedure, and it takes on the role of a Deferasirox CEP holder for the record. Additionally, the data presented in the Deferasirox CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Deferasirox DMF.
A Deferasirox CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Deferasirox CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Deferasirox suppliers with CEP (COS) on PharmaCompass.
A Deferasirox written confirmation (Deferasirox WC) is an official document issued by a regulatory agency to a Deferasirox manufacturer, verifying that the manufacturing facility of a Deferasirox active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Deferasirox APIs or Deferasirox finished pharmaceutical products to another nation, regulatory agencies frequently require a Deferasirox WC (written confirmation) as part of the regulatory process.
click here to find a list of Deferasirox suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deferasirox as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deferasirox API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deferasirox as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deferasirox and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deferasirox NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deferasirox suppliers with NDC on PharmaCompass.
Deferasirox Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deferasirox GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Deferasirox GMP manufacturer or Deferasirox GMP API supplier for your needs.
A Deferasirox CoA (Certificate of Analysis) is a formal document that attests to Deferasirox's compliance with Deferasirox specifications and serves as a tool for batch-level quality control.
Deferasirox CoA mostly includes findings from lab analyses of a specific batch. For each Deferasirox CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deferasirox may be tested according to a variety of international standards, such as European Pharmacopoeia (Deferasirox EP), Deferasirox JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deferasirox USP).